<code id='C9AD68AB38'></code><style id='C9AD68AB38'></style>
    • <acronym id='C9AD68AB38'></acronym>
      <center id='C9AD68AB38'><center id='C9AD68AB38'><tfoot id='C9AD68AB38'></tfoot></center><abbr id='C9AD68AB38'><dir id='C9AD68AB38'><tfoot id='C9AD68AB38'></tfoot><noframes id='C9AD68AB38'>

    • <optgroup id='C9AD68AB38'><strike id='C9AD68AB38'><sup id='C9AD68AB38'></sup></strike><code id='C9AD68AB38'></code></optgroup>
        1. <b id='C9AD68AB38'><label id='C9AD68AB38'><select id='C9AD68AB38'><dt id='C9AD68AB38'><span id='C9AD68AB38'></span></dt></select></label></b><u id='C9AD68AB38'></u>
          <i id='C9AD68AB38'><strike id='C9AD68AB38'><tt id='C9AD68AB38'><pre id='C9AD68AB38'></pre></tt></strike></i>

          comprehensive

          comprehensive

          author:leisure time    Page View:9
          Buildings like hospitals and banks on a web with people operating laptops and phones — health tech coverage from STAT
          Adobe

          For years, the playbook for many companies that wanted to market digital therapeutics was stupid simple: Sell it like a prescription drug.

          But just because it was simple didn’t mean it was going to work.

          advertisement

          The bankruptcy of Pear Therapeutics last year proved that selling software-based treatments like drugs is harder than anticipated. Pear received Food and Drug Administration clearance for its app treating substance use disorders and insomnia but insurers mostly refused to cover the novel treatments. Even after hitting roadblock after roadblock, the company stuck to its original plan and ended up vaporizing over $400 million in investment before finally throwing in the towel.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          leisure time

          George Santos makes 1st court appearance after pleading not guilty to 13 counts
          George Santos makes 1st court appearance after pleading not guilty to 13 counts

          1:57GeorgeSantosarrivesatfederalcourtJune30,2023,inCentralIslip,N.Y.JohnMinchillo/APRep.GeorgeSantos

          read more
          PBMs drew scrutiny in House hearing — and so did pharma
          PBMs drew scrutiny in House hearing — and so did pharma

          Rep.JamesComer,chairoftheHouseOversightCommitteeKevinDietsch/GettyImagesWASHINGTON—Congresswantstore

          read more
          Medical leaders decry Supreme Court decision on affirmative action
          Medical leaders decry Supreme Court decision on affirmative action

          STEFANIREYNOLDS/AFPviaGettyImagesMedicalleadersonThursdayreactedswiftlytotheSupremeCourt’sdecisionto

          read more

          Readout Newsletter: Sarepta, Alnylam, and Royalty Pharma

          RubyWallauforSTATWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechne